Arvinas, Inc. (NASDAQ:ARVN) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Arvinas, Inc. (NASDAQ:ARVN) have been given an average recommendation of “Moderate Buy” by the sixteen ratings firms that are covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $34.53.

ARVN has been the subject of a number of research analyst reports. Oppenheimer lowered Arvinas from an “outperform” rating to a “market perform” rating in a report on Tuesday, March 11th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arvinas in a research note on Friday, February 7th. Citigroup decreased their price target on shares of Arvinas from $28.00 to $19.00 and set a “neutral” rating on the stock in a research report on Friday, March 7th. Guggenheim cut their price objective on shares of Arvinas from $57.00 to $32.00 and set a “buy” rating for the company in a research report on Thursday, March 13th. Finally, Wedbush downgraded Arvinas from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $57.00 to $12.00 in a research report on Wednesday, March 12th.

Arvinas Trading Up 5.0 %

NASDAQ:ARVN opened at $6.95 on Friday. The firm has a market capitalization of $477.97 million, a PE ratio of -2.51 and a beta of 2.30. Arvinas has a 1 year low of $5.94 and a 1 year high of $38.56. The firm’s fifty day simple moving average is $12.58 and its 200 day simple moving average is $19.18.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same period in the prior year, the company earned ($2.53) EPS. As a group, analysts anticipate that Arvinas will post -3.81 EPS for the current fiscal year.

Insider Activity at Arvinas

In other Arvinas news, insider Ian Taylor sold 9,020 shares of the stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.71, for a total transaction of $150,724.20. Following the sale, the insider now owns 159,121 shares of the company’s stock, valued at $2,658,911.91. This represents a 5.36 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO John G. Houston sold 31,338 shares of the business’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $16.72, for a total transaction of $523,971.36. Following the completion of the transaction, the chief executive officer now directly owns 1,157,480 shares of the company’s stock, valued at approximately $19,353,065.60. This represents a 2.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 50,230 shares of company stock valued at $769,402 in the last ninety days. Insiders own 5.23% of the company’s stock.

Institutional Trading of Arvinas

A number of hedge funds and other institutional investors have recently modified their holdings of ARVN. Rhumbline Advisers lifted its holdings in Arvinas by 3.8% during the 1st quarter. Rhumbline Advisers now owns 91,210 shares of the company’s stock worth $640,000 after buying an additional 3,333 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Arvinas by 11,283.8% in the first quarter. GAMMA Investing LLC now owns 4,212 shares of the company’s stock valued at $300,000 after acquiring an additional 4,175 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in Arvinas in the fourth quarter worth about $28,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Arvinas by 0.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 433,531 shares of the company’s stock worth $8,311,000 after purchasing an additional 3,047 shares during the last quarter. Finally, Voloridge Investment Management LLC acquired a new position in Arvinas during the 4th quarter valued at about $749,000. Institutional investors and hedge funds own 95.19% of the company’s stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.